Terence Flynn
Stock Analyst at Morgan Stanley
(3.98)
# 558
Out of 4,851 analysts
192
Total ratings
56.44%
Success rate
8.38%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Equal-Weight | $12 → $11 | $6.95 | +58.27% | 9 | May 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $24 → $22 | $9.60 | +129.17% | 6 | May 9, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $140 → $132 | $111.15 | +18.76% | 3 | May 6, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $15 → $10 | $9.53 | +4.93% | 10 | May 5, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $346 → $348 | $323.97 | +7.42% | 9 | May 1, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $241 → $250 | $187.34 | +33.45% | 16 | Apr 28, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $164 → $169 | $153.22 | +10.30% | 21 | Apr 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,146 → $1,124 | $765.84 | +46.77% | 19 | Apr 9, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $328 → $330 | $287.01 | +14.98% | 8 | Apr 9, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $16.21 | +288.65% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $38.05 | -15.90% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $113 → $106 | $78.27 | +35.43% | 16 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $12.19 | +39.52% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $7.67 | +43.42% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $47.95 | -18.67% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $23.39 | +32.54% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $22.00 | +436.36% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $3.41 | +955.72% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $33.44 | +52.51% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $128.10 | +31.15% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $1.54 | +419.48% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $131.86 | +230.65% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $305.31 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.31 | - | 1 | Jul 21, 2017 |
Arvinas
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $6.95
Upside: +58.27%
Arcus Biosciences
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $9.60
Upside: +129.17%
BioNTech SE
May 6, 2025
Maintains: Overweight
Price Target: $140 → $132
Current: $111.15
Upside: +18.76%
Organon & Co.
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.53
Upside: +4.93%
United Therapeutics
May 1, 2025
Maintains: Equal-Weight
Price Target: $346 → $348
Current: $323.97
Upside: +7.42%
AbbVie
Apr 28, 2025
Maintains: Overweight
Price Target: $241 → $250
Current: $187.34
Upside: +33.45%
Johnson & Johnson
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $164 → $169
Current: $153.22
Upside: +10.30%
Eli Lilly and Company
Apr 9, 2025
Maintains: Overweight
Price Target: $1,146 → $1,124
Current: $765.84
Upside: +46.77%
Amgen
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $287.01
Upside: +14.98%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $16.21
Upside: +288.65%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $38.05
Upside: -15.90%
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $78.27
Upside: +35.43%
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $12.19
Upside: +39.52%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $7.67
Upside: +43.42%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $47.95
Upside: -18.67%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $23.39
Upside: +32.54%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $22.00
Upside: +436.36%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $3.41
Upside: +955.72%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $33.44
Upside: +52.51%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $128.10
Upside: +31.15%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $1.54
Upside: +419.48%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $131.86
Upside: +230.65%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $305.31
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -